文献速递前列腺癌

40岁起基于人群的前列腺特异性抗原筛查效果评估

The Effects of Population-based Prostate-specific Antigen Screening Beginning at Age 40.
PubMed 文献 · Urology · 2017-08-24

研究随访1052名40余岁男性至2010年,中位随访17.2年,比较接受前列腺癌检测与常规护理人群的活检、低危前列腺癌诊断及前列腺癌死亡风险。结果显示40岁起检测使活检风险增加2.4倍、低危前列腺癌诊断风险增加2.2倍,但未观察到前列腺癌死亡风险降低,作者指出需更长随访确认。

要点

  • 40-49岁接受前列腺癌检测者活检风险为常规护理人群的2.4倍(HR 2.4,95%CI 1.8-3.3)。
  • 40岁起检测者低危前列腺癌诊断风险为常规护理人群的2.2倍(HR 2.2,95%CI 1.12-4.0)。
  • 早十年启动检测者任一年龄的活检和前列腺癌诊断风险分别高2.2倍和1.7倍。

核心结论

  • 40岁起前列腺癌检测显著增加活检风险和低危前列腺癌诊断,但在此低危人群中未观察到前列腺癌死亡风险的降低。
  • 鉴于前列腺癌自然史,作者认为需要更长随访以确认该发现。

研究设计与样本

  • 纵向随访研究,1990年至2010年随访1052名40余岁男性。
  • 随机选取268名男性接受每两年一次的前列腺癌检测,包括PSA检测、经直肠超声和直肠指检。
  • 对照组为609名代表性人群,其中159名从50余岁开始前列腺癌检测。
  • 比较检测组与常规护理人群的前列腺活检、前列腺癌诊断或前列腺癌死亡风险。

主要发现

  • 中位随访17.2年。
  • 40-49岁接受检测者活检风险为常规护理人群的2.4倍(HR 2.4,95%CI 1.8-3.3)。
  • 40-49岁接受检测者低危前列腺癌诊断风险为常规护理人群的2.2倍(HR 2.2,95%CI 1.12-4.0)。
  • 早十年启动检测者任一年龄的活检风险为2.2倍(HR 2.2,95%CI 1.4-3.5),前列腺癌诊断风险为1.7倍(HR 1.7,95%CI 1.1-2.7)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出鉴于前列腺癌自然史,需要更长随访以确认该发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate population-based prostate cancer (CaP) testing of men in their 40s, given the paucity of prospective data evaluating the consequences of prostate-specific antigen (PSA) testing in younger men for CaP. MATERIALS AND METHODS: A total of 1052 men in their 40s were followed longitudinally for prostate outcomes, from 1990 to 2010. A random subset of 268 men was selected to undergo biennial CaP testing including PSA testing, transrectal ultrasound, and a digital rectal examination. A representative population of 609 men with a subset of 159 men who also began CaP testing in their 50s was also evaluated as a comparison group. Risk of prostate biopsy (PBx), CaP, or death from CaP was compared between CaP-tested and the routine-care population cohort. RESULTS: Median follow-up was 17.2 years. Men aged 40-49, who underwent CaP testing were 2.4 times more likely to undergo a PBx (hazard ratio [HR] 2.4 95% confidence interval [CI] 1.8-3.3) and 2.2 times more likely to be diagnosed with low-risk CaP (HR 2.2, 95% CI 1.12-4.0). Those initiating CaP testing a decade earlier were 2.2 times and 1.7 times more likely to be biopsied and be diagnosed with CaP for any given age (HR 2.2 95% CI 1.4-3.5 and 1.7 95% CI 1.1-2.7, respectively). CONCLUSION: CaP testing in men beginning at age 40 resulted in a significant increase in the risk of PBx and diagnosis of low-risk CaP, without a measurable reduction in risk of CaP-death in this low-risk population. However, given the natural history of CaP, a longer follow-up is needed to confirm this finding.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Weight CJ, Narayan VM, Smith D, et al. The Effects of Population-based Prostate-specific Antigen Screening Beginning at Age 40. Urology. 2017. PMID: 28842211. doi:10.1016/j.urology.2017.08.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。